J B Echouffo-Tcheugui1,2, K M Narayan2, D Weisman3, S H Golden4,5, B G Jaar4,6,7. 1. Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 2. Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 3. Department of Medicine, MedStar Health System, Baltimore, MD, USA. 4. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5. Welch Prevention Center, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. 6. Division of Nephrology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7. Nephrology Center of Maryland, Baltimore, MD, USA.
Abstract
AIMS: To assess the effect of prediabetes (impaired fasting glucose and/or impaired glucose tolerance) on the incidence of chronic kidney disease. METHODS: PubMed and EMBASE were searched (for studies published up to March 2015). Effects estimated from cohort studies reporting the relationship of prediabetes to incident chronic kidney disease [kidney damage (microalbuminuria, albuminuria or proteinuria) and/or decreased glomerular filtration rate] were pooled using a random-effects model meta-analysis. RESULTS: Nine cohort studies with a total of 185 452, mainly Asian and white, participants were followed for a total of 835 146 person-years. In eight cohort studies defining impaired fasting glucose as fasting glucose 6.1-6.9 mmol/l, the summary relative risk of chronic kidney disease after adjustment for established risk factors was 1.11 (95% CI 1.02-1.21). When a study defining impaired fasting glucose as fasting glucose 5.6-6.9 mmol/dl was added, the overall relative risk of chronic kidney disease was 1.12 (95% CI 1.02-1.21). Exclusion of the only study with information on impaired glucose tolerance did not change the relative risk (1.12; 95% CI 1.02-1.21). There was no evidence of publication bias (P value for Egger test = 0.12). CONCLUSION: Prediabetes is modestly associated with an increase in chronic kidney disease risk, but this remains to be robustly confirmed. Chronic kidney disease screening among people with prediabetes, and aggressive management of prediabetes in those with chronic kidney disease may be warranted.
AIMS: To assess the effect of prediabetes (impaired fasting glucose and/or impaired glucose tolerance) on the incidence of chronic kidney disease. METHODS: PubMed and EMBASE were searched (for studies published up to March 2015). Effects estimated from cohort studies reporting the relationship of prediabetes to incident chronic kidney disease [kidney damage (microalbuminuria, albuminuria or proteinuria) and/or decreased glomerular filtration rate] were pooled using a random-effects model meta-analysis. RESULTS: Nine cohort studies with a total of 185 452, mainly Asian and white, participants were followed for a total of 835 146 person-years. In eight cohort studies defining impaired fasting glucose as fasting glucose 6.1-6.9 mmol/l, the summary relative risk of chronic kidney disease after adjustment for established risk factors was 1.11 (95% CI 1.02-1.21). When a study defining impaired fasting glucose as fasting glucose 5.6-6.9 mmol/dl was added, the overall relative risk of chronic kidney disease was 1.12 (95% CI 1.02-1.21). Exclusion of the only study with information on impaired glucose tolerance did not change the relative risk (1.12; 95% CI 1.02-1.21). There was no evidence of publication bias (P value for Egger test = 0.12). CONCLUSION:Prediabetes is modestly associated with an increase in chronic kidney disease risk, but this remains to be robustly confirmed. Chronic kidney disease screening among people with prediabetes, and aggressive management of prediabetes in those with chronic kidney disease may be warranted.
Authors: João Sérgio Neves; Simon Correa; Rute Baeta Baptista; Miguel Bigotte Vieira; Sushrut S Waikar; Finnian R Mc Causland Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Sun H Kim; Irwin G Brodsky; Ranee Chatterjee; Sangeeta R Kashyap; William C Knowler; Emilia Liao; Jason Nelson; Richard Pratley; Neda Rasouli; Ellen M Vickery; Mark Sarnak; Anastassios G Pittas Journal: Clin J Am Soc Nephrol Date: 2021-08 Impact factor: 10.614